Nanotized curcumin‐benzothiophene conjugate: A potential combination for treatment of cerebral malaria

Ghosh, Anup K.; Banerjee, Tanushree

doi:10.1002/iub.2394

Cited by 9 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a previous study illustrated that nanonization of CUR could enhance its in vitro activity against P. falciparum by 10-fold ( 27 ). Recent exploration of combining CUR with other antimalarial drugs in nanoformulations have also presented encouraging results in the rodent malaria model ( 32 – 34 ). It is worthy to be noticed that, besides its direct cytotoxic effect on parasites, the immunomodulatory and anti-inflammatory effects of CUR have also been demonstrated to enhance parasite-infected erythrocyte phagocytosis, suppress inflammation, protect against endothelial brain damage caused by parasite-infected erythrocyte sequestration, and prevent parasite relapse ( 19 , 20 ).…”

Section: Discussionmentioning

confidence: 99%

In vitro interaction of naphthoquine with ivermectin, atovaquone, curcumin, and ketotifen in the asexual blood stage of Plasmodium falciparum 3D7

Liu,

Li,

et al. 2024

Microbiol Spectr

View full text Add to dashboard Cite

Naphthoquine is a promising candidate for antimalarial combination therapy. Its combination with artemisinin has demonstrated excellent efficacy in clinical trials conducted across various malaria-endemic areas. A co-formulated combination of naphthoquine and azithromycin has also shown high clinical efficacy for malaria prophylaxis in Southeast Asia. Developing new combination therapies using naphthoquine will provide additional arsenal responses to the growing threat of artemisinin resistance. Furthermore, due to its long half-life, the possible interaction of naphthoquine with other drugs also needs attention. However, studies on its pharmacodynamic interactions with other drugs are still limited. In this study, the in vitro interactions of naphthoquine with ivermectin, atovaquone, curcumin, and ketotifen were evaluated in the asexual stage of Plasmodium falciparum 3D7. By using the combination index analysis and the SYBR Green I-based fluorescence assay, different interaction patterns of selected drugs with naphthoquine were revealed. Curcumin showed a slight but significant synergistic interaction with naphthoquine at lower effect levels, and no antagonism was observed across the full range of effect levels for all tested ratios. Atovaquone showed a potency decline when combined with naphthoquine. For ivermectin, a significant antagonism with naphthoquine was observed at a broad range of effect levels below 75% inhibition, although no significant interaction was observed at higher effect levels. Ketotifen interacted with naphthoquine similar to ivermectin, but significant antagonism was observed for only one tested ratio. These findings should be helpful to the development of new naphthoquine-based combination therapy and the clinically reasonable application of naphthoquine-containing therapies. IMPORTANCE Pharmacodynamic interaction between antimalarials is not only crucial for the development of new antimalarial combination therapies but also important for the appropriate clinical use of antimalarials. The significant synergism between curcumin and naphthoquine observed in this study suggests the potential value for further development of new antimalarial combination therapy. The finding of a decline in atovaquone potency in the presence of naphthoquine alerts to a possible risk of treatment or prophylaxis failure for atovaquone–proguanil following naphthoquine-containing therapies. The observation of antagonism between naphthoquine and ivermectin raised a need for concern about the applicability of naphthoquine-containing therapy in malaria-endemic areas with ivermectin mass drug administration deployed. Considering the role of atovaquone–proguanil as a major alternative when first-line artemisinin-based combination therapy is ineffective and the wide implementation of ivermectin mass drug administration in malaria-endemic countries, the above findings will be important for the appropriate clinical application of antimalarials involving naphthoquine-containing therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro interaction of naphthoquine with ivermectin, atovaquone, curcumin, and ketotifen in the asexual blood stage of Plasmodium falciparum 3D7

Liu,

Li,

et al. 2024

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Finally, Ghosh and Banerjee prepared a curcumin‐(3‐bromo‐N‐(4‐fluorobenzyl)‐benzo[b]thiophene‐2‐carboxamide) conjugate (cur‐compound 6; Ghosh & Banerjee, 2020). In vitro treatment of P .…”

Section: Nanomaterials In the Fight Against Malariamentioning

confidence: 99%

Nanotherapeutics against malaria: A decade of advancements in experimental models

Avalos‐Padilla,

Fernàndez‐Busquets

2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Malaria, caused by different species of protists of the genus Plasmodium, remains among the most common causes of death due to parasitic diseases worldwide, mainly for children aged under 5. One of the main obstacles to malaria eradication is the speed with which the pathogen evolves resistance to the drug schemes developed against it. For this reason, it remains urgent to find innovative therapeutic strategies offering sufficient specificity against the parasite to minimize resistance evolution and drug side effects. In this context, nanotechnology‐based approaches are now being explored for their use as antimalarial drug delivery platforms due to the wide range of advantages and tuneable properties that they offer. However, major challenges remain to be addressed to provide a cost‐efficient and targeted therapeutic strategy contributing to malaria eradication. The present work contains a systematic review of nanotechnology‐based antimalarial drug delivery systems generated during the last 10 years.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease

show abstract

“…Improvement in biodistribution of quinine by NCEUD and increase in the half-life of elimination of quinine in vivo suggest it as a potential alternative for the treatment of malaria ( Michels et al, 2019 ). The nanoformulation of curcumin in combination with the compound benzothiophene 6 (3-bromine-N-(4-fluorobenzyl)-benzo[b]thiophene-2-carboxamide) showed sustained release of curcumin, increased stability and solubility in aqueous medium, and antimalarial activity in in vivo and in vitro experiments ( Ghosh and Banerjee, 2020 ).…”

Section: Resistance To Antimalarialsmentioning

confidence: 99%

Potential of nanoformulations in malaria treatment

Chaves

Moraes²,

Ferrarini³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Malaria is caused by the protozoan Plasmodium sp and affects millions of people worldwide. Its clinical form ranges from asymptomatic to potentially fatal and severe. Current treatments include single drugs such as chloroquine, lumefantrine, primaquine, or in combination with artemisinin or its derivatives. Resistance to antimalarial drugs has increased; therefore, there is an urgent need to diversify therapeutic approaches. The disease cycle is influenced by biological, social, and anthropological factors. This longevity and complexity contributes to the records of drug resistance, where further studies and proposals for new therapeutic formulations are needed for successful treatment of malaria. Nanotechnology is promising for drug development. Preclinical formulations with antimalarial agents have shown positive results, but only a few have progressed to clinical phase. Therefore, studies focusing on the development and evaluation of antimalarial formulations should be encouraged because of their enormous therapeutic potential.

show abstract

Nanotized curcumin‐benzothiophene conjugate: A potential combination for treatment of cerebral malaria

Cited by 9 publications

References 28 publications

In vitro interaction of naphthoquine with ivermectin, atovaquone, curcumin, and ketotifen in the asexual blood stage of Plasmodium falciparum 3D7

In vitro interaction of naphthoquine with ivermectin, atovaquone, curcumin, and ketotifen in the asexual blood stage of Plasmodium falciparum 3D7

Nanotherapeutics against malaria: A decade of advancements in experimental models

Potential of nanoformulations in malaria treatment

Contact Info

Product

Resources

About